Mutations in the protease gene associated with virological failure to lopinavir-containing regimens in clinical samples
- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1758-2652
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Mutations in the protease gene associated with virological failure to lopinavir-containing regimens in clinical samples ; volume:11 ; number:1 ; day:10 ; month:11 ; year:2008 ; pages:1 ; date:12.2008
Journal of the International AIDS Society / International AIDS Society ; 11, Heft 1 (10.11.2008), 1, 12.2008
- Urheber
-
Santos, JR
- Beteiligte Personen und Organisationen
-
Llibre, JM
Pérez-Álvarez, N.
Domingo, P.
Miralles, C.
Schapiro, J.
Clotet, B.
SpringerLink (Online service)
- DOI
-
10.1186/1758-2652-11-S1-P191
- URN
-
urn:nbn:de:1111-2016052054598
- Rechteinformation
-
Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
-
14.08.2025, 10:52 MESZ
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Santos, JR
- Llibre, JM
- Pérez-Álvarez, N.
- Domingo, P.
- Miralles, C.
- Schapiro, J.
- Clotet, B.
- SpringerLink (Online service)
Ähnliche Objekte (12)
Virological and immunological response to three boosted protease inhibitor regimens
Predictive factors of virological success to salvage regimens containing protease inhibitors in HIV-1 infected children
Relating protease inhibitor resistance at time of virological failure with drug exposure
Sustained virological response 12 versus sustained virological response 24 as evaluation endpoints in chronic hepatitis C virus Egyptian patients treated with sofosbuvir-based regimens
Virological failure and predictors in patients with clinical and immunological failures to first-line ARV regimens in Vietnam
Suitability of different diagnostic platforms for virological testing of blood samples from cornea donors
Suitability of different diagnostic platforms for virological testing of blood samples from cornea donors
Suitability of Different Diagnostic Platforms for Virological Testing of Blood Samples from Cornea Donors
Alternative methods to analyse the impact of HIV mutations on virological response to antiviral therapy
Prevalence of resistance and HIV-1 protease mutation patterns after failures with fosamprenavir-containing regimens
Lipometabolic side-effects of three ritonavir-boosted double protease inhibitor regimens without reverse transcriptase inhibitors
Pre-treatment minority HIV-1 drug resistance mutations and long term virological outcomes: is prediction possible?
Virological and immunological response to three boosted protease inhibitor regimens
Predictive factors of virological success to salvage regimens containing protease inhibitors in HIV-1 infected children
Relating protease inhibitor resistance at time of virological failure with drug exposure
Sustained virological response 12 versus sustained virological response 24 as evaluation endpoints in chronic hepatitis C virus Egyptian patients treated with sofosbuvir-based regimens
Virological failure and predictors in patients with clinical and immunological failures to first-line ARV regimens in Vietnam
Suitability of different diagnostic platforms for virological testing of blood samples from cornea donors
Suitability of different diagnostic platforms for virological testing of blood samples from cornea donors
Suitability of Different Diagnostic Platforms for Virological Testing of Blood Samples from Cornea Donors
Alternative methods to analyse the impact of HIV mutations on virological response to antiviral therapy
Prevalence of resistance and HIV-1 protease mutation patterns after failures with fosamprenavir-containing regimens
Lipometabolic side-effects of three ritonavir-boosted double protease inhibitor regimens without reverse transcriptase inhibitors
Pre-treatment minority HIV-1 drug resistance mutations and long term virological outcomes: is prediction possible?
Virological and immunological response to three boosted protease inhibitor regimens
Predictive factors of virological success to salvage regimens containing protease inhibitors in HIV-1 infected children
Relating protease inhibitor resistance at time of virological failure with drug exposure
Sustained virological response 12 versus sustained virological response 24 as evaluation endpoints in chronic hepatitis C virus Egyptian patients treated with sofosbuvir-based regimens
Virological failure and predictors in patients with clinical and immunological failures to first-line ARV regimens in Vietnam
Suitability of different diagnostic platforms for virological testing of blood samples from cornea donors
Suitability of different diagnostic platforms for virological testing of blood samples from cornea donors
Suitability of Different Diagnostic Platforms for Virological Testing of Blood Samples from Cornea Donors
Alternative methods to analyse the impact of HIV mutations on virological response to antiviral therapy
Prevalence of resistance and HIV-1 protease mutation patterns after failures with fosamprenavir-containing regimens
Lipometabolic side-effects of three ritonavir-boosted double protease inhibitor regimens without reverse transcriptase inhibitors